source
- Pharma access plans rise to 69% of late-stage drugs but gaps remain for non-communicable diseasesA new analysis shows that many large drug makers are expanding programs to make medicines available in low- and middle‑income markets, but progress is uneven across disease areas. Access plans now…
- Coherus trims workforce by 30% as Gyre Therapeutics also cuts staff after acquisitionCoherus Oncology announced a 30% reduction in its workforce as part of a reorganization that narrows its pipeline. The cuts follow a decision to deprioritize a combination therapy across multiple…